Bone Biologics Corp Stock Debt To Equity
| BBLG Stock | USD 2.73 0.07 2.50% |
Fundamental analysis of Bone Biologics allows traders to better anticipate movements in Bone Biologics' stock price by examining its financial health and performance throughout various phases of its business cycle.
| Last Reported | Projected for Next Year | ||
| Debt To Equity | (0.77) | (0.81) |
Bone | Debt To Equity | Build AI portfolio with Bone Stock |
Bone Biologics Corp Company Debt To Equity Analysis
Bone Biologics' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Bone Biologics Debt To Equity | -0.81 |
Most of Bone Biologics' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bone Biologics Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Bone Debt To Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for Bone Biologics is extremely important. It helps to project a fair market value of Bone Stock properly, considering its historical fundamentals such as Debt To Equity. Since Bone Biologics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bone Biologics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bone Biologics' interrelated accounts and indicators.
Click cells to compare fundamentals
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
Bone Liabilities And Stockholders Equity
Liabilities And Stockholders Equity |
|
Bone Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bone Biologics' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bone Biologics could also be used in its relative valuation, which is a method of valuing Bone Biologics by comparing valuation metrics of similar companies.Bone Biologics is currently under evaluation in debt to equity category among its peers.
Bone Biologics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bone Biologics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bone Biologics' managers, analysts, and investors.Environmental | Governance | Social |
Bone Fundamentals
| Return On Equity | -1.29 | ||||
| Return On Asset | -0.78 | ||||
| Current Valuation | 1.64 M | ||||
| Shares Outstanding | 1.61 M | ||||
| Shares Owned By Insiders | 9.29 % | ||||
| Shares Owned By Institutions | 0.37 % | ||||
| Number Of Shares Shorted | 46.24 K | ||||
| Price To Earning | (15.45) X | ||||
| Price To Book | 1.51 X | ||||
| EBITDA | (4.11 M) | ||||
| Net Income | (4.11 M) | ||||
| Cash And Equivalents | 5.45 M | ||||
| Cash Per Share | 0.53 X | ||||
| Total Debt | 377.71 K | ||||
| Current Ratio | 80.11 X | ||||
| Book Value Per Share | 5.34 X | ||||
| Cash Flow From Operations | (4.12 M) | ||||
| Short Ratio | 0.03 X | ||||
| Earnings Per Share | (23.04) X | ||||
| Target Price | 22.5 | ||||
| Beta | 1.22 | ||||
| Market Capitalization | 4.38 M | ||||
| Total Asset | 3.86 M | ||||
| Retained Earnings | (85.02 M) | ||||
| Working Capital | 3.48 M | ||||
| Current Asset | 1.07 M | ||||
| Current Liabilities | 2.16 M | ||||
| Net Asset | 3.86 M |
About Bone Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bone Biologics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bone Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bone Biologics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Check out Bone Biologics Piotroski F Score and Bone Biologics Altman Z Score analysis. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bone Biologics. If investors know Bone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bone Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bone Biologics Corp is measured differently than its book value, which is the value of Bone that is recorded on the company's balance sheet. Investors also form their own opinion of Bone Biologics' value that differs from its market value or its book value, called intrinsic value, which is Bone Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bone Biologics' market value can be influenced by many factors that don't directly affect Bone Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bone Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bone Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bone Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.